

Press Release



International research award goes to Dr. Karl Kolter

- **International Pharmaceutical Excipients Council Foundation presents new award in New Orleans**
- **Industry Research Achievement in Excipient Technology Award honors long-standing research excellence in the area of novel pharmaceutical excipients**

NEW ORLEANS, LA, November 16, 2010 – Dr. Karl Kolter, BASF Head of Pharmaceutical Excipients Research and Development was honored at the AAPS Annual Meeting and Exposition with the 2010 International Pharmaceutical Excipients Council Foundation (IPEC) Industry Research Achievement in Excipient Technology. Dr. Kolter received the newly established award in honor of his outstanding history of research into novel pharmaceutical excipients. "This award is a very special endorsement of many years of excipient development research and makes me very proud," Dr. Karl Kolter commented, adding "It shows that our innovative work in this complex area is appreciated by the industry."

Dr. Kolter has been working for BASF since 1993. He has developed more than 22 novel pharmaceutical excipients and has published over 120 research papers. Dr. Kolter's most recent accomplishments are Kollicoat[®] IR, a film-coating system for tablets, and the novel excipient Soluplus[®] – the new solubilizer launched in 2009 and the recipient of the Convention of Pharmaceutical Ingredients and Intermediates (CPhI) Silver Innovation Award.

November 16, 2010

P 482/10e

Bastian Timm

Telefon: +49 621 60-48237

Fax: +49 621 60-48928

bastian.timm@basf.com

Andres Christian Orthofer

Telefon :+41 27 766 – 1606

Fax : +41 27 766 – 1660

[andres-](mailto:andres-christian.orthofer@basf.com)

christian.orthofer@basf.com

BASF SE

67056 Ludwigshafen, Germany

Phone:+49 621 60-0

<http://www.basf.com>

Corporate Media Relations

Phone: +49 621 60-20916

Fax: +49 621 60-92693

presse.kontakt@basf.com

BASF's Soluplus helps customers in the pharmaceutical industry to develop and produce innovative drug products containing active ingredients that could not have been formulated with conventional excipients.

"This award is a tremendous motivation booster to keep on developing innovative excipients in the future," said Dr. Kolter. BASF plans to continue launching at least one novel pharmaceutical excipient every year to reinforce the company's leadership in this area. It makes BASF one of the few remaining excipient manufacturers to conduct groundbreaking research into innovative new excipients and bring them to market on a regular basis.

About BASF's Pharma Ingredients & Services

BASF produces and markets a broad range of active ingredients and excipients, as well as exclusive synthesis services for the pharmaceutical industry. These products are made using the latest technologies, to the highest quality standards and in compliance with cGMP guidelines. Further information can be found at www.pharma-ingredients.basf.com.

BASF - The Chemical Company.

BASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics and performance products to agricultural products, fine chemicals and oil and gas. As a reliable partner, BASF creates chemistry to help its customers in virtually all industries to be more successful. With its high-value products and intelligent solutions, BASF plays an important role in finding answers to global challenges, such as climate protection, energy efficiency, nutrition and mobility. BASF posted sales of more than €50 billion in 2009 and had approximately 105,000 employees as of the end of the year. Further information on BASF is available on the Internet at www.basf.com.